A Phase III Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM) (KEYNOTE 183)

Trial Profile

A Phase III Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM) (KEYNOTE 183)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 05 Jun 2018

At a glance

  • Drugs Pembrolizumab (Primary) ; Pomalidomide (Primary) ; Dexamethasone
  • Indications Multiple myeloma
  • Focus Registrational; Therapeutic Use
  • Acronyms KEYNOTE-183
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology
    • 05 Jun 2018 Results evaluating overall survival (OS), safety and objective response rates (ORR) among patients who developed irAEs and those who did not in two trials of pembro in MM (KEYNOTE 183 and 185) presented at the 54th Annual Meeting of the American Society of Clinical Oncology
    • 05 Jul 2017 According to a Merck & Co. media release, this trial has been placed on full clinical hold by the US FDA due to safety concerns observed in KEYNOTE-183 and KEYNOTE-185 trials. All patients enrolled in this trial will discontinue investigational treatment with pembrolizumab.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top